Anaphylaxis caused by pegylated recombinant human granulocyte colony-stimulating factor.
J Oncol Pharm Pract
; 29(3): 727-730, 2023 Apr.
Article
in En
| MEDLINE
| ID: mdl-35833225
ABSTRACT
INTRODUCTION:
Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF), is commonly used to prevent and/or treat neutropenia caused by tumor chemotherapy and radiotherapy with reduced clearance, increased plasma half-life, sustained biologic activity, and good safety. PEG-rhG-CSF anaphylaxis was rare. CASE REPORT A 55-year-old male Non-Hodgkin lymphoma patient appeared with chest tightness, increased heart rate, and decreased blood pressure after taking PEG-rhG-CSF used as a primary treatment for neutropenia caused by chemoradiotherapy. The patient's anaphylaxis is likely due to PEG-rhG-CSF. MANAGEMENT ANDOUTCOME:
0.9% sodium chloride 250â mL and dexamethasone sodium phosphate injection 5â mg were carried out. After close observation, the symptoms were improved. Two months later, the patient was readministered with PEG-rhG-CSF and anaphylaxis reoccurred. After the last contact with PEG-rhG-CSF, the patient was prescribed rhG-CSF for many times and did not experience any adverse reactions.DISCUSSION:
PEGylated drugs are not free of risk and immune-mediated adverse events are of concern. PEG is a substance capable of triggering an immune response. The mechanism of PEG involved IgE-mediated anaphylaxis and non-IgE-mediated anaphylaxis, and requires further research. PEGylated drugs are not free of risk and immune-mediated adverse events are of concern.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Anaphylaxis
/
Neutropenia
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Oncol Pharm Pract
Journal subject:
FARMACIA
Year:
2023
Type:
Article
Affiliation country:
China